Targeting PAK1 is effective against cutaneous squamous cell carcinoma in a syngenic mouse model

By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of...

Full description

Saved in:
Bibliographic Details
Published inCancer Science Vol. 115; no. 8; pp. 2839 - 2845
Main Authors Okumura, Kazuhiro, Morinaga, Takao, Saito, Megumi, Tokunaga, Yurika, Otoyama, Keisuke, Tanaka, Sora, Isogai, Eriko, Kawazu, Masahito, Togashi, Yosuke, Hasegawa, Yoshinori, Wakabayashi, Yuichi
Format Journal Article
LanguageEnglish
Published England Wiley 01.08.2024
John Wiley & Sons, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS‐PAK1‐1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA‐induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS‐PAK1‐1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA‐sequencing analysis on the engrafted tumors indicates that NVS‐PAK1‐1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan‐keratin‐positive regions and potentially elevated infiltration of CD8‐positive immune cells in NVS‐PAK1‐1‐treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC. PAK1 inhibitor treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo.
AbstractList By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS-PAK1-1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA-induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS-PAK1-1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA-sequencing analysis on the engrafted tumors indicates that NVS-PAK1-1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan-keratin-positive regions and potentially elevated infiltration of CD8-positive immune cells in NVS-PAK1-1-treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC.
By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS‐PAK1‐1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA‐induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS‐PAK1‐1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA‐sequencing analysis on the engrafted tumors indicates that NVS‐PAK1‐1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan‐keratin‐positive regions and potentially elevated infiltration of CD8‐positive immune cells in NVS‐PAK1‐1‐treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC. PAK1 inhibitor treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo.
By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS‐PAK1‐1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA‐induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS‐PAK1‐1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA‐sequencing analysis on the engrafted tumors indicates that NVS‐PAK1‐1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan‐keratin‐positive regions and potentially elevated infiltration of CD8‐positive immune cells in NVS‐PAK1‐1‐treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC.
By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS-PAK1-1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA-induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS-PAK1-1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA-sequencing analysis on the engrafted tumors indicates that NVS-PAK1-1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan-keratin-positive regions and potentially elevated infiltration of CD8-positive immune cells in NVS-PAK1-1-treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC.By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS-PAK1-1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA-induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS-PAK1-1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA-sequencing analysis on the engrafted tumors indicates that NVS-PAK1-1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan-keratin-positive regions and potentially elevated infiltration of CD8-positive immune cells in NVS-PAK1-1-treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC.
By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1 has been considered to promote cancer development, its overall function remains poorly understood. To clarify the functional significance of Pak1 in detail, we sought to evaluate the possible effect of an allosteric inhibitor against PAK1 (NVS‐PAK1‐1) on a syngeneic mouse model. To this end, we established two cell lines, 9AS1 and 19AS1, derived from DMBA/TPA‐induced squamous cell carcinoma (SCC) that engrafted in FVB mice. Based on our present results, NVS‐PAK1‐1 treatment significantly inhibited the growth of tumors derived from 9AS1 and 19AS1 cells in vitro and in vivo. RNA‐sequencing analysis on the engrafted tumors indicates that NVS‐PAK1‐1 markedly potentiates the epidermal cell differentiation and enhances the immune response in the engrafted tumors. Consistent with these observations, we found an expansion of Pan‐keratin‐positive regions and potentially elevated infiltration of CD8‐positive immune cells in NVS‐PAK1‐1‐treated tumors as examined by immunohistochemical analyses. Together, our present findings strongly suggest that PAK1 is tightly linked to the development of SCC, and that its inhibition is a promising therapeutic strategy against SCC.
Author Takao Morinaga
Keisuke Otoyama
Yosuke Togashi
Kazuhiro Okumura
Sora Tanaka
Yuichi Wakabayashi
Megumi Saito
Yurika Tokunaga
Eriko Isogai
Masahito Kawazu
Yoshinori Hasegawa
Author_xml – sequence: 1
  givenname: Kazuhiro
  surname: Okumura
  fullname: Okumura, Kazuhiro
  organization: Chiba Cancer Center Research Institute
– sequence: 2
  givenname: Takao
  surname: Morinaga
  fullname: Morinaga, Takao
  organization: Chiba Cancer Center Research Institute
– sequence: 3
  givenname: Megumi
  surname: Saito
  fullname: Saito, Megumi
  organization: Chiba Cancer Center Research Institute
– sequence: 4
  givenname: Yurika
  surname: Tokunaga
  fullname: Tokunaga, Yurika
  organization: Chiba Cancer Center Research Institute
– sequence: 5
  givenname: Keisuke
  surname: Otoyama
  fullname: Otoyama, Keisuke
  organization: Chiba Cancer Center Research Institute
– sequence: 6
  givenname: Sora
  surname: Tanaka
  fullname: Tanaka, Sora
  organization: Chiba Cancer Center Research Institute
– sequence: 7
  givenname: Eriko
  surname: Isogai
  fullname: Isogai, Eriko
  organization: Chiba Cancer Center Research Institute
– sequence: 8
  givenname: Masahito
  surname: Kawazu
  fullname: Kawazu, Masahito
  organization: Chiba Cancer Center Research Institute
– sequence: 9
  givenname: Yosuke
  orcidid: 0000-0001-9910-0164
  surname: Togashi
  fullname: Togashi, Yosuke
  organization: Okayama University
– sequence: 10
  givenname: Yoshinori
  surname: Hasegawa
  fullname: Hasegawa, Yoshinori
  organization: Kazusa DNA Research Institute
– sequence: 11
  givenname: Yuichi
  orcidid: 0000-0002-8861-2954
  surname: Wakabayashi
  fullname: Wakabayashi, Yuichi
  email: yuichi_wakabayashi@chiba‐cc.jp
  organization: Chiba Cancer Center Research Institute
BackLink https://cir.nii.ac.jp/crid/1871429166527071488$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/38898727$$D View this record in MEDLINE/PubMed
BookMark eNp10Utr3DAQAGBREpo0zaF_oAjaQ3twopct6bgsfZFACk3PYiyNFxVbTiy7Zf99tXHSQyE6jObwzTDMvCJHaUxIyBvOLnh5lx7yBW-Eal6QUy6VrTRjzdFDrivLpDgh5znHltVGWaGMeElOpDHWaKFPibuFaYdzTDv6fXPFacwUuw79HH8jhR3ElGfqlxkSjkum-X6B4ZB47HvqYfIxjQPQmCjQvE87TNHTg8ASA_avyXEHfcbzx_-M_Pz86Xb7tbq--fJtu7muvFKyqbpgulYw3YCyEBBNLWzHQm2CbhlqjoyBVQw850pCkAEBBWvrOmiDoePyjHxY-95N4_2CeXZDzIch18GdZJoZUVtpC333H_01LlMq0xVlmRYNt3VRbx_V0g4Y3N0UB5j27ml1BXxcgZ_GnCfs_hHO3OEyrlzGPVym2MvV_ok97p-Hbrv58VTxfq1IMbqy5BK50VwJy5umFpqV3Bj5F6pHmEg
Cites_doi 10.1158/0008-5472.CAN-04-3480
10.1016/j.jid.2018.12.027
10.1021/acs.jmedchem.2c00756
10.1038/s41598-017-11561-x
10.1186/s12885-017-3432-0
10.3390/cells12192373
10.1016/j.jid.2024.01.021
10.3389/fchem.2021.707317
10.1093/carcin/bgg067
10.1093/carcin/bgs250
10.1016/j.jid.2022.02.009
10.1038/s41388-020-1323-3
10.1021/acsmedchemlett.5b00102
10.1007/s10555-008-9168-1
10.1016/j.canlet.2019.12.020
10.1093/hmg/ddab106
10.1042/BST20160134
ContentType Journal Article
Copyright 2024 The Author(s). published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024 The Author(s). published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
– notice: 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
– notice: 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID RYH
24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1111/cas.16246
DatabaseName CiNii Complete
Wiley-Blackwell Open Access Titles
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

Publicly Available Content Database
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1349-7006
EndPage 2845
ExternalDocumentID 38898727
10_1111_cas_16246
CAS16246
Genre researchArticle
Journal Article
GrantInformation_xml – fundername: Takeda Foundation
– fundername: Japan Society for the Promotion of Science
  funderid: JP19K07494; JP22K07012
– fundername: Japan Society for the Promotion of Science
  grantid: JP22K07012
– fundername: Japan Society for the Promotion of Science
  grantid: JP19K07494
GroupedDBID ---
.3N
.GA
05W
0R~
10A
1OC
24P
29B
36B
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52W
52X
5GY
5HH
5LA
5VS
66C
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
88E
8FE
8FH
8FI
8FJ
8UM
930
A01
A03
AAFWJ
AAHHS
AAZKR
ABCQN
ABUWG
ACCFJ
ACCMX
ACXQS
ADBBV
ADKYN
ADPDF
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFBPY
AFEBI
AFKRA
AFPKN
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BY8
CCPQU
CS3
D-6
D-7
D-E
D-F
DR2
DU5
E3Z
EBS
EMB
EMOBN
EX3
F00
F01
F04
F5P
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
HZI
HZ~
IAO
IHR
ITC
IX1
J0M
K.9
K48
KQ8
LC2
LC3
LH4
LK8
LP6
LP7
M1P
M7P
MK4
N04
N05
N9A
O9-
OIG
OK1
OVD
P2P
P2X
P2Z
P4B
P4D
PHGZM
PHGZT
PIMPY
PROAC
PSQYO
Q11
ROL
RPM
RX1
RYH
SJN
SV3
TEORI
UB1
UKHRP
W8V
WOW
WQJ
WXI
XG1
~IA
~WT
.55
.Y3
2WC
31~
3O-
53G
7.U
ABEML
ACSCC
AFFNX
AFZJQ
BFHJK
CAG
COF
DIK
EJD
FIJ
GODZA
HF~
HOLLA
IPNFZ
LW6
SUPJJ
WIN
WRC
X7M
ZXP
AAYXX
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c4436-fd8fb2076a49adee8529f0d58d7b0e71e00a940ac1143ad3deae20b55d78edf13
IEDL.DBID DR2
ISSN 1347-9032
1349-7006
IngestDate Tue Aug 05 09:22:57 EDT 2025
Wed Aug 13 01:33:21 EDT 2025
Mon Jul 21 05:55:50 EDT 2025
Tue Jul 01 01:31:19 EDT 2025
Wed Jan 22 17:15:10 EST 2025
Thu Jun 26 23:30:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords PAK1 inhibitor
mouse
DMBA/TPA
syngenic model
squamous cell carcinoma
Language English
License Attribution-NonCommercial
2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4436-fd8fb2076a49adee8529f0d58d7b0e71e00a940ac1143ad3deae20b55d78edf13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-9910-0164
0000-0002-8861-2954
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.16246
PMID 38898727
PQID 3090726195
PQPubID 4378882
PageCount 7
ParticipantIDs proquest_miscellaneous_3070825939
proquest_journals_3090726195
pubmed_primary_38898727
crossref_primary_10_1111_cas_16246
wiley_primary_10_1111_cas_16246_CAS16246
nii_cinii_1871429166527071488
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate August 2024
PublicationDateYYYYMMDD 2024-08-01
PublicationDate_xml – month: 08
  year: 2024
  text: August 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Tokyo
PublicationTitle Cancer Science
PublicationTitleAlternate Cancer Sci
PublicationYear 2024
Publisher Wiley
John Wiley & Sons, Inc
Publisher_xml – name: Wiley
– name: John Wiley & Sons, Inc
References 2021; 9
2017; 7
2022; 142
2015; 6
2023; 12
2017; 17
2020; 472
2017; 45
2020; 39
2003; 24
2005; 65
2019; 139
2022; 65
2024
2021; 30
2012; 33
2009; 28
e_1_2_10_12_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_10_1
e_1_2_10_11_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
References_xml – year: 2024
  article-title: Deletion of Pak1 in CD11c positive cells resistance to mouse skin carcinogenesis
  publication-title: J Invest Dermatol
– volume: 139
  start-page: 1459
  issue: 7
  year: 2019
  end-page: 1469
  article-title: A polymorphic variant in p19Arf confers resistance to chemically induced skin tumors by activating the p53 pathway
  publication-title: J Invest Dermatol
– volume: 17
  start-page: 431
  issue: 1
  year: 2017
  article-title: Depletion of p21‐activated kinase 1 up‐regulates the immune system of APC∆14/+ mice and inhibits intestinal tumorigenesis
  publication-title: BMC Cancer
– volume: 65
  start-page: 15627
  issue: 23
  year: 2022
  end-page: 15641
  article-title: Development and utility of a PAK1‐selective degrader
  publication-title: J Med Chem
– volume: 45
  start-page: 79
  issue: 1
  year: 2017
  end-page: 88
  article-title: Targeting PAK1
  publication-title: Biochem Soc Trans
– volume: 39
  start-page: 4756
  issue: 24
  year: 2020
  end-page: 4769
  article-title: Pak1 maintains epidermal stem cells by regulating Langerhans cells and is required for skin carcinogenesis
  publication-title: Oncogene
– volume: 142
  start-page: 2323
  issue: 9
  year: 2022
  end-page: 2333.e12
  article-title: Functional polymorphism in Pak1‐3' untranslated region alters skin tumor susceptibility by alternative polyadenylation
  publication-title: J Invest Dermatol
– volume: 9
  year: 2021
  article-title: E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points
  publication-title: Front Chem
– volume: 24
  start-page: 1159
  issue: 7
  year: 2003
  end-page: 1165
  article-title: Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis
  publication-title: Carcinogenesis
– volume: 33
  start-page: 2260
  issue: 11
  year: 2012
  end-page: 2268
  article-title: Independent genetic control of early and late stages of chemically induced skin tumors in a cross of a Japanese wild‐derived inbred mouse strain, MSM/Ms
  publication-title: Carcinogenesis
– volume: 7
  issue: 1
  year: 2017
  article-title: The parathyroid hormone regulates skin tumour susceptibility in mice
  publication-title: Sci Rep
– volume: 65
  start-page: 3179
  issue: 8
  year: 2005
  end-page: 3184
  article-title: Pak1 phosphorylation of snail, a master regulator of epithelial‐to‐mesenchyme transition, modulates snail's subcellular localization and functions
  publication-title: Cancer Res
– volume: 28
  start-page: 51
  issue: 1–2
  year: 2009
  end-page: 63
  article-title: Pak protein kinases and their role in cancer
  publication-title: Cancer Metastasis Rev
– volume: 6
  start-page: 776
  issue: 7
  year: 2015
  end-page: 781
  article-title: Optimization of a dibenzodiazepine hit to a potent and selective allosteric PAK1 inhibitor
  publication-title: ACS Med Chem Lett
– volume: 30
  start-page: 1607
  issue: 17
  year: 2021
  end-page: 1617
  article-title: PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of neurofibromatosis type 2 (NF2)
  publication-title: Hum Mol Genet
– volume: 472
  start-page: 8
  year: 2020
  end-page: 18
  article-title: Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti‐tumour immunity through down‐regulation of PD‐L1
  publication-title: Cancer Lett
– volume: 12
  start-page: 2373
  issue: 19
  year: 2023
  article-title: PAK1 and therapy resistance in melanoma
  publication-title: Cells
– ident: e_1_2_10_13_1
  doi: 10.1158/0008-5472.CAN-04-3480
– ident: e_1_2_10_10_1
  doi: 10.1016/j.jid.2018.12.027
– ident: e_1_2_10_18_1
  doi: 10.1021/acs.jmedchem.2c00756
– ident: e_1_2_10_9_1
  doi: 10.1038/s41598-017-11561-x
– ident: e_1_2_10_14_1
  doi: 10.1186/s12885-017-3432-0
– ident: e_1_2_10_16_1
  doi: 10.3390/cells12192373
– ident: e_1_2_10_4_1
  doi: 10.1016/j.jid.2024.01.021
– ident: e_1_2_10_17_1
  doi: 10.3389/fchem.2021.707317
– ident: e_1_2_10_12_1
  doi: 10.1093/carcin/bgg067
– ident: e_1_2_10_8_1
  doi: 10.1093/carcin/bgs250
– ident: e_1_2_10_11_1
  doi: 10.1016/j.jid.2022.02.009
– ident: e_1_2_10_3_1
  doi: 10.1038/s41388-020-1323-3
– ident: e_1_2_10_5_1
  doi: 10.1021/acsmedchemlett.5b00102
– ident: e_1_2_10_2_1
  doi: 10.1007/s10555-008-9168-1
– ident: e_1_2_10_15_1
  doi: 10.1016/j.canlet.2019.12.020
– ident: e_1_2_10_7_1
  doi: 10.1093/hmg/ddab106
– ident: e_1_2_10_6_1
  doi: 10.1042/BST20160134
SSID ssib058492482
ssib002224741
ssib048395060
ssib002484371
ssj0036494
ssib050729863
Score 2.4315743
Snippet By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1...
By taking advantage of forward genetic analysis in mice, we have demonstrated that Pak1 plays a crucial role during DMBA/TPA skin carcinogenesis. Although Pak1...
SourceID proquest
pubmed
crossref
wiley
nii
SourceType Aggregation Database
Index Database
Publisher
StartPage 2839
SubjectTerms 9,10-Dimethyl-1,2-benzanthracene - toxicity
Allosteric properties
Animals
Antibodies
Carcinogenesis
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - metabolism
Carcinoma, Squamous Cell - pathology
CD8 antigen
CD8-Positive T-Lymphocytes - drug effects
CD8-Positive T-Lymphocytes - metabolism
Cell differentiation
Cell Differentiation - drug effects
Cell growth
Cell Line, Tumor
Cell Proliferation - drug effects
Disease Models, Animal
DMBA/TPA
Female
Genes
Genetic analysis
Immune response
Keratin
Kinases
Metastases
Mice
Morphology
mouse
p21-Activated Kinases - antagonists & inhibitors
p21-Activated Kinases - genetics
p21-Activated Kinases - metabolism
PAK1 inhibitor
Phosphorylation
Sequence analysis
Skin cancer
Skin Neoplasms - drug therapy
Skin Neoplasms - genetics
Skin Neoplasms - metabolism
Skin Neoplasms - pathology
Squamous cell carcinoma
Syngeneic grafts
syngenic model
Tetradecanoylphorbol Acetate
Tumors
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Na9VAEB9sBfEi1s9oW1bx4CW43x8neZSWolQEW3i3sMluJIfmtea9g_-9M0neU0F7CYHkMJnZzPx-u7P7A3jXJptkzKbkPqpSixTKuhVIXK1rvHEt8iIiihdf7PmV_rQ0y3nCbZjbKrc5cUzUadXQHPkHxZHGEdw3H29uS1KNotXVWUJjD-7T0WXU0uWWO8KlrA6TqK12ZeBKzicLUScPCYoJKwn3_lGP9vqu-xfU_Bu5jqXn7DE8mjEjW0xBPoB7uX8CDy7mVfGnUF2O7dxYhNjXxWfBuoFNbRqYyVj8jtx_WLNmgzAwI89nw-0mEuFnNGnPGhIT6lfXkXU9i2z4SZutuobRG5mNQjnP4Ors9PLkvJyFE8pGa2XLNvm2ltzZqENMOXsjQ8uT8cnVPDuROY9B89ggGVIxqZRjlrw2JjmfUyvUc9jvV31-CaxWKqsoai9y0Cb5iPAgONlkZVSwPhTwduu-6mY6H6Pa8gr0cTX6uIAjdGyFX4NXgRQNi6Cw1khH26e8L-Bw6_Jq_oWG6nfAC3ize4yDn5wzOayihIUUF00q4MUUqp0VyvvgEZ0V8H6M3f_Nq04W38abV3fb8RoeSoQ0U_vfIeyvf2zyEUKSdX08jrtfKh7aeA
  priority: 102
  providerName: ProQuest
Title Targeting PAK1 is effective against cutaneous squamous cell carcinoma in a syngenic mouse model
URI https://cir.nii.ac.jp/crid/1871429166527071488
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.16246
https://www.ncbi.nlm.nih.gov/pubmed/38898727
https://www.proquest.com/docview/3090726195
https://www.proquest.com/docview/3070825939
Volume 115
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9UwEB52VxBfvF-qu4coPvjSJWnu-HRcdlmUXQ7rLpwHoaRNKkXsUXv6oL_eSW-4oiC-lEJTmMxkku9LJjMALyuvfOaCTKlxPBXM27SoGBJXpUsjdYW8KBLFs3N1eiXeruV6B15Pd2GG_BDzhlv0jH6-jg7uivYXJ48lwZjKREy3HWO1IiC6mFNHcSXsUNBW6NRSno1ZhWIUz_zntbVot6nrP8HM66i1X3ZO7sCHSeAh2uTTYbctDssfv-Vy_M8e3YXbIxwly2H83IOd0NyHm2fjgfsDyC_7SHFc38hq-Y6RuiVDBAhOksR9dDWiS1J2iDDDpmtJ-7VzcS-BxPMAUsY6Rc3msyN1Qxxpv8d7XHVJYotA-ho8D-Hq5Pjy6DQdazKkpRBcpZU3VZFRrZywzodgZGYr6qXxuqBBs0Cps4K6EnkWd5774EJGCym9NsFXjD-CvWbThCdACs4Dd6wwLFghvXGIPKzOysAlt8rYBF5M1sm_DKk38omyoKryXlUJHKDdcuwNPhmyP1xfmVIy0_FmljEJ7E8WzUfvbHNOLdWROsoEns-f0a-icgaF5XEuRPaMIiXweBgJsxTcGGsQ-CXwqrfn38XLj5bv-5en_970GdzKEDkNUYb7sLf91oUDRD7bYgG7mVjhU6_1Am68OT5fXSz6XYRFP_h_AtVr_rk
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB71IQGXimeb0oJBIHGJ8CNO7ANCS2m1ZburCrZSb8aJHZRDs23TFeqf4jcyzqOABNx6iSIlipzP45nvs8cegFelSx23XsZUWREnzOk4LxkK1zQrlMxK1EVBKE5n6fgk-XQqT1fgx7AXJqRVDj6xddRuUYQ58reCoowLdF--P7-IQ9WosLo6lNDozGLir7-jZGveHX7E_n3N-cH-fG8c91UF4iJJRBqXTpU5R_luE22d90pyXVInlcty6jPmKbU6obZApSCsE85bz2kupcuUdyUT-N1VWMdPUXQE6x_2Z8efB98v0kR3ZXSTLNZU8P4so5A7FEqYsZQHpv1bBFytq-pv5PZPrtwGu4P7sNGzVDLqzOoBrPj6IdyZ9uvwj8DM2wRyDHvkeDRhpGpIlxiCvpPYb7ZC0kmKJRJPv1g2pLlY2jDFQMIyASlC-aJ6cWZJVRNLmuuwvasqSHjDk7Y0z2M4uRVQn8Bavaj9FpBcCC8syxXzOpFOWSQkOuOFF1LoVOkIXg7wmfPuRA4zKBnE2LQYR7CLwBr8G7wyFIUYdlmaSp6FDVtKRbAzQG76QduYXyYWwYubxzjcAjgdYCa4SBTV2KQINruuummFUEor5IMRvGn77t_NM3ujL-3N9v_b8RzujufTI3N0OJs8hXscCVWXfLgDa1eXS7-LhOgqf9ZbIYGvt234PwEbqhnS
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB61Raq4IN4NbcEgkLhEjV-xfUBo1bJqWVpVopX2ZpzYQTmQbZuuUP8av45xHgtIwK2XKFKiyPk8nvk-e-wBeF353DMXZJppx1NBvUmLiqJwzVWppapQF0WheHySH56Lj3M5X4Mf416YmFY5-sTOUftFGefI93iGMi7SfblXDWkRpwfT9xeXaawgFVdax3IavYnMws13lG_tu6MD7Os3jE0_nO0fpkOFgbQUgudp5XVVMJTyThjnQ9CSmSrzUntVZEHRkGXOiMyVqBq489wHF1hWSOmVDr6iHL-7DncUlzSOMTVfiT2eC9MX1BUqNRlnw6lGMYsoFjOjOYuc-7dYuN7U9d9o7p-suQt70_twb-CrZNIb2ANYC81D2DweVuQfgT3rUskxAJLTyYySuiV9igh6UeK-uhrpJymXSEHDYtmS9nLp4mQDiQsGpIyFjJrFN0fqhjjS3sSNXnVJ4huBdEV6HsP5rUD6BDaaRRO2gBScB-5ooWkwQnrtkJoYxcrAJTe5Ngm8GuGzF_3ZHHbUNIix7TBOYBeBtfg3eKUoDzEA0zyXTMWtW1onsDNCbofh29pfxpbAy9VjHHgRnB4wG50lymtsUgJP-65atYJrbTQywwTedn337-bZ_cnn7ubZ_9vxAjbR3O2no5PZNtxlyKz6LMQd2Li-WoZdZEbXxfPOBAl8uW2b_wlduxyi
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+PAK1+is+effective+against+cutaneous+squamous+cell+carcinoma+in+a+syngenic+mouse+model&rft.jtitle=Cancer+science&rft.au=Okumura%2C+Kazuhiro&rft.au=Morinaga%2C+Takao&rft.au=Saito%2C+Megumi&rft.au=Tokunaga%2C+Yurika&rft.date=2024-08-01&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=115&rft.issue=8&rft.spage=2839&rft.epage=2845&rft_id=info:doi/10.1111%2Fcas.16246&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_cas_16246
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon